Ipsen: Combined Shareholders’ Meeting of 31 May 2013

  Ipsen: Combined Shareholders’ Meeting of 31 May 2013

         Availability of documentation for the Shareholders’ Meeting

Business Wire

PARIS -- May 2, 2013

Regulatory News:

The Shareholders of the Company are invited to participate in the Combined
Shareholders’ Meeting of Ipsen SA (Paris:IPN) to be held on Friday 31 May 2013
at 3 pm (Paris time) at La Maison des Arts et Métiers (salon La
Rochefoucauld), 9 bis avenue d’Iéna, 75116 Paris, France.

The preliminary notice of meeting containing the agenda and the proposed
resolutions has been published in the Bulletin des Annonces Légales
Obligatoires (BALO) dated 17 April 2013 and is available on Ipsen’s website at
the following address: www.ipsen.com.

Documents and information relating to this Meeting will be made available to
shareholders under the conditions provided for by legal and regulatory
provisions in force.

In accordance with applicable regulatory provisions:

  *Registered shareholders can, until the fifth day (inclusive) before the
    Meeting, request from the Company supply of the said documents, including
    at their request, by way of an electronic mail. For holders of bearer
    shares, the exercise of this right is subject to the presentation of a
    certificate of attendance in the bearer share accounts kept by the
    empowered intermediary;
  *All shareholders can consult these documents at the Company’s
    headquarters.

About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by 3 franchises: neurology / Dysport^®,
endocrinology / Somatuline^® and uro-oncology / Decapeptyl^®. Moreover, the
Group has an active policy of partnerships. Ipsen's R&D is focused on its
innovative and differentiated technological platforms, peptides and toxins. In
2012, R&D expenditure totaled close to €250 million, representing more than
20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s
shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code:
FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The
Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I
American Depositary Receipt (ADR) program, which trade on the over-the-counter
market in the United States under the symbol IPSEY. For more information on
Ipsen, visit www.ipsen.com.

Contact:

Media
Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Email: didier.veron@ipsen.com
or
Financial Community
Pierre Kemula
Vice President Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
Email: pierre.kemula@ipsen.com
or
Brigitte Le Guennec
Media and Public Relations Officer
Tel. : +33 (0)1 58 33 51 17
Fax : 01 58 33 50 58
Email :  brigitte.le.guennec@ipsen.com
or
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
Email: stephane.durant.des.aulnois@ipsen.com
 
Press spacebar to pause and continue. Press esc to stop.